Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ACADEMIA
ACADEMIA
- Dapagliflozin Significantly Reduces Plasma Glucose in PIII Study in Japan, Findings Reported at ADA
June 25, 2013
- SCJ Statement Calls for Close Consultation with Experts in Planning Japanese Version of NIH
June 25, 2013
- Makers Should Venture into Drug Development Using iPS, CiRA Adviser Asonuma Says
June 25, 2013
- More Treatment Options for FD Patients with Acofide Launch: Prof. Kinoshita of Shimane University
June 11, 2013
- Clinical Pharmacology Network to Go Into Operation with 8 Institutions
June 6, 2013
- Japan College of Rheumatology Issues Guidelines on Xeljanz Use
June 6, 2013
- Cetuximab Add-on Therapy Fails to Improve PFS in Operable Colorectal Liver Metastasis Patients: ASCO
June 4, 2013
- Japan College of Rheumatology to Collaborate with Pfizer on PMS, Warns that Non-RA Specialists More Inclined to Prescribe Xeljanz
May 31, 2013
- Researcher Wearing Two Hats Should Disclose Affiliation with Greater Interests in Trials: Japan Hypertension Society
May 30, 2013
- JAMS Recognizes Violation of COI Reporting Rules over Diovan Papers
May 28, 2013
- Nat’l University Hospitals Sharing Information of Drug Purchase Prices through Central Database
May 7, 2013
- JAMS Greatly Concerned Over Diovan Paper Retractions: President Takaku
April 25, 2013
- Stivarga May Become Third/Forth-Line Colon Cancer Therapy in Japan: Prof. Sugihara
April 25, 2013
- RA Treatment Guidelines to Reflect Patients’ Values and Economic Considerations as Well as Evidence
April 24, 2013
- Osaka University Hospital to Initiate PET Microdose Study This Fall: Prof. Tomono
April 23, 2013
- New COPD Guidelines Recommend LAMA, LABA on Equal Footing
April 23, 2013
- Japan College of Rheumatology Airs Concerns over Safety of Xeljanz
April 11, 2013
- Kyoto Heart Study Chief Investigator Resigns after Diovan Paper Retractions
March 1, 2013
- Diovan Paper Contained “Careless Errors,” but “No Impact on Findings”: Chief Investigator Comments on Retraction
February 7, 2013
- JSGM Calls for 80% Generic Share, 30% Reduction in NHI Prices of Long-Listed Drugs by End of FY2017
December 6, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…